Literature DB >> 31879467

Altering the natural history of rheumatoid arthritis: The role of immunotherapy and biologics in orthopaedic care.

Steven J Girdler1, Ivan Ye1, Ray Tang1, Noah Kirschner2.   

Abstract

Rheumatoid Arthritis (RA) is an idiopathic disease characterized by systemic inflammation, persistent synovitis, and the presence of autoantibodies. Because of the musculoskeletal deformity caused by RA, multiple orthopaedic procedures are regularly performed as part of the treatment. The changing rates of surgery and the rise in new efficacious medical therapy have improved the prognosis for patients with RA. This review will discuss the natural history of rheumatoid arthritis, common medications used to treat it, how disease progression has changed as a function of new biologic immunotherapy, and the role of orthopaedic intervention in this new landscape of advanced rheumatoid care.
© 2019 Professor P K Surendran Memorial Education Foundation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biologics; Immunotherapy; Rheumatoid arthritis

Year:  2019        PMID： 31879467      PMCID： PMC6919343          DOI： 10.1016/j.jor.2019.06.030

Source DB:  PubMed          Journal:  J Orthop        ISSN： 0972-978X


  20 in total

Review 1.  The implications of biologic therapy for elective foot and ankle surgery in patients with rheumatoid arthritis.

Authors:  Ross Diaper; Ernest Wong; Stuart A Metcalfe
Journal:  Foot (Edinb)       Date:  2017-01-27

Review 2.  Rituximab for rheumatoid arthritis.

Authors:  Maria Angeles Lopez-Olivo; Matxalen Amezaga Urruela; Lynda McGahan; Eduardo N Pollono; Maria E Suarez-Almazor
Journal:  Cochrane Database Syst Rev       Date:  2015-01-20

3.  The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.

Authors:  R Nixon; N Bansback; A Brennan
Journal:  Rheumatology (Oxford)       Date:  2007-05-03       Impact factor: 7.580

4.  Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.

Authors:  Solbritt Rantapää-Dahlqvist; Ben A W de Jong; Ewa Berglin; Göran Hallmans; Göran Wadell; Hans Stenlund; Ulf Sundin; Walther J van Venrooij
Journal:  Arthritis Rheum       Date:  2003-10

5.  Impact of biologics on the prevalence of orthopedic surgery in the National Database of Rheumatic Diseases in Japan.

Authors:  Tetsuro Yasui; Jinju Nishino; Yuho Kadono; Toshihiro Matsui; Kozo Nakamura; Sakae Tanaka; Shigeto Tohma
Journal:  Mod Rheumatol       Date:  2010-01-08       Impact factor: 3.023

Review 6.  Methotrexate for treating rheumatoid arthritis.

Authors:  Maria Angeles Lopez-Olivo; Harish R Siddhanamatha; Beverley Shea; Peter Tugwell; George A Wells; Maria E Suarez-Almazor
Journal:  Cochrane Database Syst Rev       Date:  2014-06-10

7.  Tofacitinib versus methotrexate in rheumatoid arthritis.

Authors:  Eun Bong Lee; Roy Fleischmann; Stephen Hall; Bethanie Wilkinson; John D Bradley; David Gruben; Tamas Koncz; Sriram Krishnaswami; Gene V Wallenstein; Chuanbo Zang; Samuel H Zwillich; Ronald F van Vollenhoven
Journal:  N Engl J Med       Date:  2014-06-19       Impact factor: 91.245

8.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Authors:  Michael E Weinblatt; Edward C Keystone; Daniel E Furst; Larry W Moreland; Michael H Weisman; Charles A Birbara; Leah A Teoh; Steven A Fischkoff; Elliot K Chartash
Journal:  Arthritis Rheum       Date:  2003-01

9.  Recent trends in orthopedic surgery aiming to improve quality of life for those with rheumatoid arthritis: data from a large observational cohort.

Authors:  Shigeki Momohara; Eisuke Inoue; Katsunori Ikari; Kensuke Ochi; Osamu Ishida; Koichiro Yano; Yu Sakuma; Shinji Yoshida; Takuma Koyama; Naoko Koenuma; Atsuo Taniguchi; Hisashi Yamanaka
Journal:  J Rheumatol       Date:  2014-04-01       Impact factor: 4.666

10.  Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

Authors:  Cem Gabay; Paul Emery; Ronald van Vollenhoven; Ara Dikranian; Rieke Alten; Karel Pavelka; Micki Klearman; David Musselman; Sunil Agarwal; Jennifer Green; Arthur Kavanaugh
Journal:  Lancet       Date:  2013-03-18       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.